Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6012 versus secukinumab in moderate to severe plaque psoriasis
ChiCTR2500102014Phase 3Completed
- Sponsor
- Shanghai Skin Disease Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SYS6012, secukinumab in plaque psoriasis, sponsored by Shanghai Skin Disease Hospital. Started May 2025; status: completed.
02
Drugs
SYS6012secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2500102014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102014.